anti-BRCA1 antibody product blog
Tags: Antibody; Monoclonal Antibody; BRCA1; anti-BRCA1 antibody;
The BRCA1 brca1 (Catalog #MBS219956) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s BRCA1 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistology Paraffin, Western Blot (WB).Immunofluorescence: Maximum Dilution: 1.0ug/ml;
Western Blotting: Minimum Dilution: 1.0; Maximum Dilution: 10.0ug/ml. Researchers should empirically determine the suitability of the BRCA1 brca1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The BRCA1 brca1 product has the following accession number(s) (GI #1698399) (NCBI Accession #AAC37594.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse anti BRCA1, clone 17F8 recognises both human and mouse BRCA1, otherwise known as breast cancer type 1 susceptibility protein, a tumor suppressor gene and major player in DNA damage repair, predominantly expressed in the nucleus during the S/G2 phase of the cell cycle. Along with BRCA2, BRCA1 is a high risk gene which is associated with hereditary breast and ovarian cancers, particularly at a younger age of identification. Women carrying the BRCA1 mutation have a 50-95% chance of developing breast cancer in later life, but genetic screening and increased awareness of preventative surgery, can reduce this risk significantly. Deleterious BRCA1 mutations may also increase the risk of other cancers in both males and females including pancreatic cancer, although in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations. BRCA1 is a key marker of triple-negative breast cancer/TNBC (ER-/PR-/HER2-), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and which lacks the benefit of specific therapy that targets the three major proteins ER/PR/HER2. Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women.Mouse anti BRCA1, clone17F8 recognises full length 220kDa BRCA1, but not the delta exon 11 splice variant. Mouse anti BRCA1, clone17F8 is well documented for use in immunohistochemistry, and studies using immunofluorescence staining, have shown that this antibody labels both cytoplasmic BRCA1 and the centromeric region (overlapping with the nucleus), and exhibits cytoplasmic staining of BRCA1 in breast cancer cell lines and nuclear staining in several non-breast cancer cell lines (Lee, et al. 1998).
Perservative Stabilisers: 0.09% Sodium Azide (NaN3)
Preparation: Purified IgG prepared by affinity chromatography on Protein G. Histology Positive Control Tissue: Breast carcinoma
Buffer Solution: Phosphate buffered saline
Target Species: Human.